These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21045708)

  • 1. Parental preferences for CDKN2A/p16 testing of minors.
    Taber JM; Aspinwall LG; Kohlmann W; Dow R; Leachman SA
    Genet Med; 2010 Dec; 12(12):823-38. PubMed ID: 21045708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress.
    Stump TK; Aspinwall LG; Kohlmann W; Champine M; Hauglid J; Wu YP; Scott E; Cassidy P; Leachman SA
    J Genet Couns; 2018 Aug; 27(4):955-967. PubMed ID: 29349527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.
    Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
    Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
    Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone.
    Taber JM; Aspinwall LG; Stump TK; Kohlmann W; Champine M; Leachman SA
    J Behav Med; 2015 Oct; 38(5):740-53. PubMed ID: 26178773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
    Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
    Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of melanoma genetic test reporting on perceived control over melanoma prevention.
    Aspinwall LG; Stump TK; Taber JM; Kohlmann W; Leaf SL; Leachman SA
    J Behav Med; 2015 Oct; 38(5):754-65. PubMed ID: 25822116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
    Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
    J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors.
    Glanz K; Volpicelli K; Kanetsky PA; Ming ME; Schuchter LM; Jepson C; Domchek SM; Armstrong K
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):607-14. PubMed ID: 23392000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic testing for familial melanoma.
    Primiero CA; Maas EJ; Wallingford CK; Soyer HP; McInerney-Leo AM
    Ital J Dermatol Venerol; 2024 Feb; 159(1):34-42. PubMed ID: 38287743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
    Levin T; Mæhle L
    Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applications of melanoma genetics.
    Gabree M; Patel D; Rodgers L
    Curr Treat Options Oncol; 2014 Jun; 15(2):336-50. PubMed ID: 24652319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDKN2A testing and genetic counseling promote reductions in objectively measured sun exposure one year later.
    Stump TK; Aspinwall LG; Drummond DM; Taber JM; Kohlmann W; Champine M; Cassidy PB; Petrie T; Liley B; Leachman SA
    Genet Med; 2020 Jan; 22(1):26-34. PubMed ID: 31371819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical genetic testing for familial melanoma in Italy: a cooperative study.
    Bruno W; Ghiorzo P; Battistuzzi L; Ascierto PA; Barile M; Gargiulo S; Gensini F; Gliori S; Guida M; Lombardo M; Manoukian S; Menin C; Nasti S; Origone P; Pasini B; Pastorino L; Peissel B; Pizzichetta MA; Queirolo P; Rodolfo M; Romanini A; Scaini MC; Testori A; Tibiletti MG; Turchetti D; Leachman SA; Bianchi Scarrà G;
    J Am Acad Dermatol; 2009 Nov; 61(5):775-82. PubMed ID: 19500876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric melanoma in melanoma-prone families.
    Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
    Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priority of Risk (But Not Perceived Magnitude of Risk) Predicts Improved Sun-Protection Behavior Following Genetic Counseling for Familial Melanoma.
    Taber JM; Aspinwall LG; Drummond DM; Stump TK; Kohlmann W; Champine M; Cassidy P; Leachman SA
    Ann Behav Med; 2021 Feb; 55(1):24-40. PubMed ID: 32415830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing.
    Aspinwall LG; Taber JM; Kohlmann W; Leaf SL; Leachman SA
    Genet Med; 2014 Nov; 16(11):846-53. PubMed ID: 24763292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant.
    Onnekink AM; Klatte DCF; van Hooft JE; van den Berg SH; van der Zwaan SMS; van Doorn R; Hinnen SCH; Potjer TP; Bleiker EMA; van Leerdam ME
    Fam Cancer; 2024 Aug; 23(3):255-265. PubMed ID: 38822936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A testing threshold in a high-risk Australian melanoma cohort: number of primaries, family history and young age of onset impact risk.
    McMeniman EK; Peach E; Lee KJ; Yanes T; Jagirdar K; Stark MS; Soyer HP; Duffy DL; McInerney-Leo AM; Sturm RA
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):e797-e798. PubMed ID: 32386439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.